Knee osteoarthritis
Conditions
Brief summary
Mean change from baseline in IL-6 concentration in SF after 2-week long treatment in study arm with naproxen compared to study arm with placebo.
Detailed description
Mean change from baseline in TNF-α concentration in SF after 2-week long treatment in study arm with naproxen compared to study arm with placebo., Mean change from baseline in IL-1β concentration in SF after 2-week long treatment in study arm with naproxen compared to study arm with placebo., Mean change from baseline in pain subscale (P1-P9) KOOS score after 2-week long treatment in study arm with naproxen compared to study arm with placebo., Mean change from baseline in symptoms subscale (S1-S7) KOOS score after 2-week long treatment in study arm with naproxen compared to study arm with placebo., Mean change from baseline in function, daily living subscale (A1-A17) KOOS score after 2-week long treatment in study arm with naproxen compared to study arm with placebo., Mean change from baseline in function, sports and recreational activities subscale (SP1-SP5) KOOS score after 2-week long treatment in study arm with naproxen compared to study arm with placebo., Mean change from baseline in quality of life subscale (Q1-Q4) KOOS score after 2-week long treatment in study arm with naproxen compared to study arm with placebo, Correlation between naproxen concetration in SF and cytokine (IL-1β, IL-6 and TNF-α) concentrations in SF after 2-week long treatment in study arm with naproxen., Correlation between naproxen concentration and pain subscale (P1-P9) KOOS score after 2-week long treatment in study arm with naproxen., Correlation between naproxen concentration in SF and symptoms subscale (S1-S7) KOOS score after 2-week long treatment in study arm with naproxen., Correlation between naproxen concentration in SF and function, daily living subscale (A1-A17) KOOS score after 2-week long treatment in study arm with naproxen., Correlation between naproxen concentration in SF and function, sports and recreational activities subscale (SP1-SP5) KOOS score after 2-week long treatment in study arm with naproxen., Correlation of naproxen concentration in SF and quality of life subscale (Q1-Q4) KOOS score after 2-week long treatment in study arm with naproxen., Determination of synovial membrane penetration index of naproxen after 2-week long treatment in study arm with naproxen.
Interventions
Sponsors
KRKA tovarna zdravil d.d. Novo mesto
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean change from baseline in IL-6 concentration in SF after 2-week long treatment in study arm with naproxen compared to study arm with placebo. | — |
Secondary
| Measure | Time frame |
|---|---|
| Mean change from baseline in TNF-α concentration in SF after 2-week long treatment in study arm with naproxen compared to study arm with placebo., Mean change from baseline in IL-1β concentration in SF after 2-week long treatment in study arm with naproxen compared to study arm with placebo., Mean change from baseline in pain subscale (P1-P9) KOOS score after 2-week long treatment in study arm with naproxen compared to study arm with placebo., Mean change from baseline in symptoms subscale (S1-S7) KOOS score after 2-week long treatment in study arm with naproxen compared to study arm with placebo., Mean change from baseline in function, daily living subscale (A1-A17) KOOS score after 2-week long treatment in study arm with naproxen compared to study arm with placebo., Mean change from baseline in function, sports and recreational activities subscale (SP1-SP5) KOOS score after 2-week long treatment in study arm with naproxen compared to study arm with placebo., Mean change from baseline | — |
Countries
Poland
Outcome results
None listed